LP-118

LP-118 is a novel, orally bioavailable small molecule inhibitor that targets the anti-apoptotic proteins B-cell lymphoma 2 (BCL2) and B-cell lymphoma-extra large (BCLXL). It is designed to induce apoptosis in cancer cells by inhibiting these proteins, which are often overexpressed in hematological malignancies and contribute to resistance against existing therapies such as venetoclax. LP-118 demonstrates potent activity against both venetoclax-naïve and -resistant chronic lymphocytic leukemia (CLL) cells, including those with the BCL2 G101V mutation. Its fine-tuned inhibition of BCLXL aims to minimize platelet toxicity—a common side effect of earlier dual inhibitors—while maintaining efficacy. Preclinical studies show that LP-118 induces mitochondrial apoptosis via efficient activation of pro-apoptotic pathways, leading to cytochrome C release and cell death. The drug is being developed for several hematologic cancers including CLL, acute myeloid leukemia (AML), multiple myeloma, precursor cell lymphoblastic leukemia-lymphoma, and small cell lung cancer[1][3][4][5][6][8].